Page contentsPage contents Key facts Decision Key facts Active substance visugromab Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000233807 PIP number EMA/PE/0000233807 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of non-small cell lung cancer Route(s) of administration All routes of administration Contact for public enquiries Catalym GmbH Tel. +49 892000664400 E-mail: info@catalym.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 19/03/2026 Compliance check done No Decision EMA/PE/0000233807: EMA decision of 19 March 2025 on the granting of a product specific waiver for visugromabAdopted Reference Number: EMADOC-1700519818-1973487 English (EN) (238.95 KB - PDF)First published: 17/06/2026 View Share this page